Company** | University/Agency/ | Type Of | Product Area | Details (Month) |
Nonprofit [Scientist] | Agreement | |||
Advanced Viral | National Cancer | Cooperative | Research on anti- | Original agreement, from 3/97, |
Research Corp. | Institute (NCI) of | Research and | tumor activity and | was extended for 1 year to 3/99 |
(OTC Bulletin | the National | Development | anti-inflammatory | (3/98) |
Board:ADVR) | Institutes of Health | Agreement/ | activity of Reticulose | |
[Howard Young] | Material Transfer | (a peptide nucleic | ||
Agreement | acid product) | |||
(CRADA/MTA) | ||||
Affymetrix Inc. | Howard Hughes | Supply | Subscription-based | Howard Hughes investigators get |
Medical Institute | agreement | academic Easy- | broad access to GeneChip probe | |
Access supply | arrays, instrumentation and soft- | |||
agreement for | ware to use in fundamental bio- | |||
custom and standard | medical research; 2.5-year agree- | |||
GeneChip expres- | ment; Affymetrix gets subscrip- | |||
sion monitoring | tion fees and fixed per-chip fees | |||
probe arrays | with a volume commitment from | |||
Howard Hughes (4/98) | ||||
Allergene Inc.* | University of | License | T cell receptor | Allergene acquired rights to pep- |
Arizona | peptide (ALG889) | tide and expects to begin Phase | ||
[Jack Marchalonis; | that can reverse | I/II trials in AIDS by end of year | ||
Ronald Watson] | some of immune | (5/98) | ||
system abnormalities | ||||
found in HIV infection | ||||
and other immune | ||||
diseases | ||||
Amrad Corp. | University of | Research | Establishment of | Tasmania has an isolated, inbred |
(Australia) | Tasmania, Menzies | collaboration | genetic epidemiol- | population with existence of |
Centre for Population | ogy unit to conduct | multigenerational historical | ||
Health Research | research on Tasma- | records; Amrad will provide | ||
[Terry Dwyer] | nian families for dis- | A$2.5M (US$1.5M) over 5 years | ||
ease genes; initial | to set up unit; Amrad has | |||
targets include | option to commercialize any drugs | |||
osteoporosis, multi- | or technology that result; Menzies | |||
ple sclerosis and | Centre gets royalties (1/98) | |||
endometriosis | ||||
ArQule Inc. | Beth Israel Dea- | Sponsored | Therapeutics for | ArQule will assess and select com- |
coness Medical | research | treating bone and | pounds from its Mapping Array | |
Center | agreement | mineral diseases, | program using Beth Israel's assays | |
[Michael Chorev] | initially osteo- | for biological actions on bone; | ||
porosis (molec- | active leads will be optimized via | |||
ular nature of | ArQule's Directed Array program; | |||
compounds ND) | ArQule will sponsor research and | |||
gets option on exclusive license | ||||
to any new drug candidates (5/98) | ||||
Biota Holdings | The Howard Florey | License; | Development of | Biota will assist institute in char- |
Ltd. (ASX:BTA; | Institute of Experi- | research | neuroactive com- | acterizing compound; Biota is |
Australia) | mental Physiology | collaboration | pound (not de- | responsible for commercializing |
and Medicine | scribed) that affects | research and will identify pharma- | ||
(Australia) | short-term memory | ceutical partners for development | ||
[Frederick | as treatment for | and commercialization (2/98) | ||
Mendelsohn] | Alzheimer's disease | |||
and other memory- | ||||
related disorders | ||||
La Trobe Univer- | Extension of | Chemical anticancer | Agreement dates from 4/97; Biota | |
sity (Australia) | research | compounds (mixed | will extend its research support | |
[Les Deady] | collaboration | topoisomerase inhib- | for another 12 months; university | |
itors) for treating | will provide scaled up chemical | |||
colon cancer and | synthesis of selected drug leads | |||
other solid tumors; | for animal studies (1/98) | |||
initiation of preclin- | ||||
ical development | ||||
Biovector | National Institutes | License | DLS technology for | Thierry, inventor of the technol- |
Therapeutics | of Health (NIH) | drug delivery (includ- | ogy, joined Biovector as director | |
SA* (France) | [Alain Thierry] | ing therapeutic | of gene therapy and delivery; the | |
proteins); delivers | NIH gets milestones and royalties | |||
DNA via subcutane- | on any products (5/98) | |||
ous or intravenous | ||||
injection | ||||
Boston Life | Harvard University | License | BCLx-gamma gene; | Boston Life gets rights to gene; |
Sciences Inc. | [Harvey Cantor] | controls apoptosis | further details ND (3/98) | |
in T cells | ||||
Cell | City of Hope | Joint | Development of | Joint venture is expansion of 2- |
Therapeutics | National Medical | venture | drugs that block | year collaboration between 2 |
Inc. | Center | oxygen carrying | parties; Cell Therapeutics will | |
molecules (including | fund 1st 2 years of joint venture | |||
reactive oxidized | and provide technology in oxi- | |||
lipids) that attack | dized lipid chemistry; City of Hope | |||
pancreas and cause | contributes its rights to human | |||
insulin resistance | leukocyte 12-lipoxygenase (gen- | |||
and other compli- | erates oxidized lipids); Cell Ther- | |||
cations of diabetes | apeutics holds 70% of joint ven- | |||
ture, City of Hope holds 30%; | ||||
financial terms ND (1/98) | ||||
Cadus | Massachusetts Insti- | License; | Development of | Project combines Cadus' yeast- |
Pharmaceutical | tute of Technology | sponsored | next-generation | based drug discovery assays with |
Corp. | [Ian Hunter] | research | biochip screening | Hunter's expertise in micro-robot- |
agreement | system; disposable | ics (living machines) (1/98) | ||
CD-sized screening | ||||
tool that will accom- | ||||
modate 100,000 | ||||
cell-based assays on | ||||
a single chip | ||||
Chiron | Stanford University | Strategic | Joint R&D program | Multiyear agreement; Chiron gets |
Diagnostics | (Medical Informatics) | partnership | to develop clinical | exclusive license to software |
(business unit of | decision support | architecture; specific terms ND | ||
Chiron Corp.) | systems for health | (1/98) | ||
care enterprises; based | ||||
on Stanford's EON | ||||
software architecture | ||||
CoCensys Inc. | Massachusetts | License | Use of neuroactive | CoCensys gets exclusive world- |
General Hospital | steroids (epalons; in- | wide rights to patent-pending | ||
cluding ganaxolone) | technology; further details ND | |||
and other gamma | (1/98) | |||
amino butyric acid | ||||
(GABA) receptor | ||||
modulators for | ||||
treating migraine | ||||
Corixa Corp. | Washington Univ- | License | Human mamma- | Corixa gets exclusive option on |
ersity, St. Louis | globin (expressed | worldwide diagnostic rights (it | ||
[Timothy Fleming; | specifically in adult | previously acquired rights to gene | ||
Mark Watson] | mammary gland) as | and gene products for use in tumor | ||
marker for breast | vaccines) (4/98) | |||
cancer detection | ||||
Cortex Pharma- | University of | License | Broad patent on use | Cortex gets rights to patent that |
ceuticals Inc. | California, Irvine | of any AMPA recep- | broaden scope of its potential pro- | |
[Gary Lynch] | tor-modulating com- | ducts (5/98) | ||
pound (which in- | ||||
creases synaptic | ||||
transmission) for | ||||
treating schizo- | ||||
phrenia | ||||
CV | The Cleveland | Research | Preclinical testing | Parties will evaluate use of cell |
Therapeutics | Clinic Foundation | collaboration | of certain of CV's | cycle inhibitors in combination |
Inc. | [Eric Topol] | small molecule cell | with drug delivery catheters and | |
cycle inhibitors | as coatings on endoluminal stents; | |||
(including CVT- | further details ND (2/98) | |||
313) to reduce | ||||
occurrence of | ||||
restenosis after | ||||
angioplasty due to | ||||
excessive prolifer- | ||||
ation of vascular cells | ||||
Cyanotech Corp. | The Scripps | License; | Production of | Cyanotech licensed the technology |
Research Institute | production | Scripps' genetically | to produce the antibody via its | |
engineered aldolase | 2nd-generation algae cultivation | |||
catalytic antibody | technology PhytoMax; Scripps | |||
38C2 in microalgae | will provide genetically engineered | |||
(for synthesis of | live microalgae containing aldolase | |||
certain anticancer | protein to Cyanotech (4/98) | |||
compounds and | ||||
other applications) | ||||
Cypros | University of | License | Compounds that | Cypros gets exclusive license to |
Pharmaceutical | Rhode Island | selectively raise | recently patented series of com- | |
Corp. | levels of adenosine | pounds; further details ND (2/98) | ||
(a naturally occur- | ||||
ring cytoprotective | ||||
agent) in ischemic | ||||
tissue | ||||
Digital Gene | The Scripps | Research | Use of Digital | This is 1st project in company's |
Technologies | Research Institute | collaboration | Gene's TOGA tech- | program of academic research |
Inc.* | [Peter Vogt; | nology (total gene | collaborations using its patented | |
Shu-Ling Fu] | expression analysis) | TOGA technology; institution gets | ||
to identify and | fee-free access to technology; | |||
isolate genes that | Digital Gene reserves rights to | |||
are differentially | commercial applications of discov- | |||
expressed in chick- | eries; institution gets share of net | |||
en cells transformed | revenues (4/98) | |||
by jun oncogene | ||||
State University of | Research | Use of Digital | This is 2nd project in program of | |
New York, | collaboration | Gene's TOGA tech- | academic research collaborations; | |
Stony Brook | nology (total gene | if any products commercialized, | ||
[Simon Halegoua] | expression analysis) | academic institution gets share of | ||
to determine full | net revenues (4/98) | |||
array of genes that | ||||
regulate the neural | ||||
actions of growth | ||||
factors and cytokines | ||||
Enzo Biochem | Hadassah University | Research | Preclinical analysis | ND (4/98) |
Inc. | Hospital (Israel) | collaboration | of various therapeu- | |
tics via Enzo's | ||||
immune modulation | ||||
technologies, includ- | ||||
ing oral tolerization | ||||
EnzyMed Inc.* | University of Iowa | Research | Testing of chemical | 5-year agreement; if any targets |
collaboration | compounds gener- | lead to marketed drugs, University | ||
ated via EnzyMed's | of Iowa shares in revenues; further | |||
Bioactiv technology | details ND (5/98) | |||
for activity against/ | ||||
affinity for biological | ||||
targets identified by | ||||
university scientists | ||||
GeneMedicine | University of | Research | Development of | GeneMedicine gets option for an |
Inc. | Texas Southwestern | collaboration | technology for tar- | exclusive license to any discover- |
Medical Center | geting and manipu- | ies or inventions; further details | ||
at Dallas | lating dendritic | ND (5/98) | ||
[Stephen Johnston; | cells, which will be | |||
Akira Takashima] | used in genetic vac- | |||
cines for cancer and | ||||
infectious diseases | ||||
Genetix | Dana-Farber | License | Use of lentiviruses | Genetix gets exclusive worldwide |
Pharmaceuticals | Cancer Institute | as gene therapy | license to issued patent and subse- | |
Inc.* | [Joseph Sodroski] | vectors | quent patent applications (2/98) | |
Genome | The Massachusetts | Research | Identification and | Massachusetts General and Tufts |
Therapeutics | General Hospital | collaboration | characterization of | will collect and analyze DNA |
Corp. | [Mason Freeman] | gene that causes | samples and histories from an | |
and Tufts University | monogenic HDL | extensive multigenerational family | ||
[Ernst Schaefer] | deficiency (low | to facilitate cloning of target gene | ||
levels of high-den- | via Genome Therapeutics' sequenc- | |||
sity lipoproteins in | ing and gene identification capa- | |||
blood; causes pre- | bilities; Genome Therapeutics | |||
mature heart | gets exclusive license to commer- | |||
disease) | cialize any products (1/98) | |||
Genzyme Corp. | St. Elizabeth's | Two research | Development of | For each separate agreement, |
Medical Center of | collaborations | gene therapy prod- | Genzyme will fund research and | |
Boston [Kenneth | ucts to treat occlu- | pay option fees; scientists get | ||
Walsh] and The | sive vascular dis- | access to Genzyme's viral and | ||
Johns Hopkins | ease: Fas ligand | nonviral vectors; Genzyme gets | ||
University School | gene therapy (to | exclusive option to license tech- | ||
of Medicine | inhibit vascular | nology (5/98) | ||
[Gregg Semenza] | smooth muscle pro- | |||
liferation after | ||||
angioplasty; Walsh) | ||||
and HIF-1 gene | ||||
therapy (hypoxia- | ||||
inducible factor-1 is | ||||
expressed by cells | ||||
exposed to subnormal | ||||
levels of oxygen; | ||||
Semenza) | ||||
Genzyme | Dana-Farber | License | Use of fusion cell | Genzyme Molecular gets option |
Molecular | Cancer Institute | technology to create | for an exclusive license to technol- | |
Oncology | [Donald Kufe] | anticancer vaccine | ogy; Genzyme Molecular will | |
(business unit of | that stimulates | fund research for 18 months (5/98) | ||
Genzyme Corp.) | immune response to | |||
tumor (dendritic | ||||
cells are fused with | ||||
tumor cells) | ||||
Hyseq Inc. | University of | Research | Use of Hyseq's se- | This is 1st collaboration under |
California, San | collaboration | quencing by hybridi- | Hyseq's pharmacogenomics | |
Francisco | zation technology to | initiatives; UCSF will collect DNA | ||
[John Kane] | detect gene loci, | samples from 20,000 genetically | ||
genome mutations | diverse individuals (many with | |||
and polymorphisms | related clinical histories); Hyseq | |||
that can be used to | gets exclusive right to commer- | |||
diagnose and treat | cialize the database and may make | |||
cardiovascular dis- | it available to 3rd parties (2/98) | |||
eases; creation of | ||||
cardiovascular poly- | ||||
morphism database | ||||
Idun | Thomas Jefferson | License; | Development of | Idun gets exclusive license to |
Pharmaceuticals | University | research | caspases and other | patent applications covering |
Inc.* | [Emad Alnemri] | collaboration | proteins that are key | certain cell death proteins; further |
regulators in apop- | details ND (1/98) | |||
tosis (includes | ||||
caspase-13, a pro- | ||||
tease; regulatory | ||||
proteins FLAMES | ||||
1 and 2 and TRAIL | ||||
receptors, members | ||||
of tumor necrosis | ||||
factor receptor | ||||
family) | ||||
Ilex Oncology | The Burnham | License | Development and | Ilex gets license to technology; |
Inc. | Institute | testing of compound | Burnham gets a warrant to buy | |
[Erkki Ruoslahti; | that links a tumor | $5M in Ilex stock at 120% premi- | ||
Renata Pasqualini] | homing peptide to | um to market; Burnham also gets | ||
chemotherapeutic | milestone payments and royalties | |||
drug doxorubicin | (3/98) | |||
(THP-dox); binds to | ||||
and destroys blood | ||||
vessels that nourish | ||||
solid tumors and | ||||
releases doxorubicin | ||||
Imutec Pharma | Harvard Medical | Research | Identification and | Imutec will fund research; further |
Inc. (TSE:IMT; | School | collaboration | characterization of | details ND (5/98) |
Canada) | [Jose Halperin] | receptor associated | ||
with anti-prolifer- | ||||
ative and anti-angio- | ||||
genic activity of | ||||
drug clotrimazole | ||||
National Cancer | License; | NCI will screen | NCI gets royalty-free license to | |
Institute (NCI) of | screening | Imutec's anticancer | compounds; further details ND | |
the National | agreement | compounds in its | (3/98) | |
Institutes of Health | panel of cancer cell | |||
lines | ||||
Interneuron | Tulane University | License | Patent that covers | Interneuron gets exclusive world- |
Pharmaceuticals | [Akira Arimura] | two forms of the | wide rights to patent and patent | |
Inc. | neuropeptide | applications; Interneuron will | ||
PACAP (pituitary | focus on developing one version | |||
adenylate cyclase | of PACAP, the 38-amino-acid | |||
activating poly- | form (PACAP38) which crosses | |||
peptide) and their | blood-brain barrier; Interneuron | |||
analogues; for | will fund research for 2 years, pay | |||
treating stroke and | up-front licensing fee, milestones | |||
other neurodegen- | and royalties (4/98) | |||
erative diseases | ||||
Megabios Corp. | University of | License; | Rheumatology; | Megabios acquired patent rights |
Pittsburgh | two research | in vivo and ex vivo | and technology portfolio; Mega- | |
[Paul Robbins; | collaborations | gene-based thera- | bios issued 0.12M shares of com- | |
Christopher Evans] | pies for joint dis- | mon stock to university in exchange | ||
eases (viral and | for exclusive license to family | |||
nonviral delivery | of patents and patent applications; | |||
systems) | Megabios established research and | |||
consulting relationships with Rob- | ||||
bins and Evans; Megabios will fund | ||||
R&D at university labs and has | ||||
started in-house research programs | ||||
in rheumatoid arthritis, osteoarthri- | ||||
tis and cartilage repair (3/98) | ||||
University of | Research | Rheumatology; | Megabios established a collabora- | |
Pittsburgh | collaboration | gene-based therapies | tion and consulting relationship | |
[Joseph Glorioso III] | for joint diseases | with Glorioso; Megabios gets | ||
(rheumatoid arthritis, | certain rights to intellectual pro- | |||
osteoarthritis, | perty and technology developed | |||
cartilage repair) | in the collaboration (4/98) | |||
Micrologix | The Protein | License; | Codevelopment of | 4-year agreement; US$1.27M will |
Biotech Inc. | Engineering | research | diagnostics and | be invested in program (50% by |
(Canada) | Network Centres | collaboration | therapeutics based | Micrologix, 50% by Canadian |
of Excellence | on synthetic ana- | National Centres of Excellence); | ||
(PENCE; Canada) | logues of family of | Micrologix gets exclusive world- | ||
[Robert Hodges; | natural antimicro- | license to technology for use in | ||
Randall Irvin] | bial peptides | human and veterinary health care | ||
and in agriculture (2/98) | ||||
Molecular | University of | Research | DNA microarray | University will provide technical |
Dynamics Inc. | Washington | collaboration | technology access | expertise while gaining early |
and Amersham | [Leroy Hood] | agreement; for con- | access to integrated microarray | |
Pharmacia | tinued development | systems; companies will provide | ||
Biotech (Sweden) | of high-throughput | microarray fabrication, hybridi- | ||
microarray system | zation and optical scanning instru- | |||
(which compares | mentation and software as well as | |||
levels of gene | matched reagents and consum- | |||
expression in normal | ables (1/98) | |||
and diseased cells) | ||||
Myriad Genetics | Rockefeller | License | Certain genes (not | Myriad gets exclusive worldwide |
Inc. | University | described) involved | license on genes and rights to all | |
in control of cancer | therapeutic and diagnostic appli- | |||
cell growth | cations (4/98) | |||
Nabi | Centers for | Cooperative | Determination of | ND (4/98) |
Disease Control | Research and | efficacy of Nabi- | ||
and Prevention | Development | Civacir (human poly- | ||
(U.S. Public Health | Agreement | clonal antibody to | ||
Service) | (CRADA) | hepatitis C virus; | ||
HCV) for preventing | ||||
or modifying HCV | ||||
infection in experi- | ||||
mentally infected | ||||
chimpanzees | ||||
Nabi | University of | License | Ring expanded | Nabi gets exclusive worldwide |
Maryland | nucleoside (RENs) | rights to make, use and sell prod- | ||
[Ramachandra | and nucleotide | ucts based on technology (5/98) | ||
Hosmane] | (RENt) technology; | |||
chemically synthe- | ||||
sized analogues with | ||||
antiviral, antimicro- | ||||
bial and antitumor | ||||
activity | ||||
Neurotech SA* | Kennedy Krieger | Research | Development of | ND (3/98) |
(France) | Institute | collaboration | endothelial cell- | |
[John Laterra] | based gene therapies | |||
for treating glio- | ||||
blastoma (targeted | ||||
delivery of anti- | ||||
tumoral peptides) | ||||
NeXstar | University of | License | CTLA-4 Blockade | NeXstar gets exclusive option to |
Pharmaceuticals | California, | technology for use | license technology; further details | |
Inc. | Berkeley | as therapeutic vac- | ND (5/98) | |
[James Allison] | cine for cancer (may | |||
be able to stimulate | ||||
immune system to | ||||
block tumor growth) | ||||
Oncor Inc. | Yale University | License | Rolling circle ampli- | Oncor exercised option from 1996 |
[Paul Lizardi] | fication technology | agreement to license RCAT and | ||
(RCAT; isothermic | obtained certain rights to technol- | |||
nucleic acid ampli- | ogy; Oncor also will participate in | |||
fication system) for | limited liability company together | |||
use in diagnostics | with Yale University and Molec- | |||
for cancer, infec- | ular Staging Inc. to commercial- | |||
tious diseases, mo- | ize RCAT through sublicenses | |||
lecular genotyping, | (3/98) | |||
pharmacogenetics | ||||
Origen | North Carolina | License | Avian embryonic | Origen gets exclusive license to |
Therapeutics | State University | stem cell technol- | broad technology platform for | |
Inc.* | [James Petitte] | ogies to enable | all applications (1/98) | |
genetic engineering | ||||
of poultry; goal to | ||||
produce recombi- | ||||
nant human protein | ||||
therapeutics in | ||||
chicken eggs | ||||
OSI | Vanderbilt | Research | Small molecule | Collaboration ranges from drug |
Pharmaceuticals | University | collaboration | drugs for treating | discovery and development to |
Inc. | Diabetes Center | Type II diabetes; | early clinical testing; further | |
initial focus on 4 | details ND (4/98) | |||
targets, including | ||||
hexokinase II and | ||||
other gene expres- | ||||
sion targets | ||||
Osiris | The Institute for | Research | Role of mesenchy- | 3-year agreement; Osiris will pro- |
Therapeutics | Cancer Research at | collaboration | mal stem cells (MSC) | vide $1M in research funding in |
Inc.* | the University of | and other stromal | exchange for exclusive worldwide | |
Genoa (Italy) | progenitor cells in | rights to technology (3/98) | ||
[Ranieri Cancedda] | regenerating tissues | |||
following damage due | ||||
to cancer chemothera- | ||||
py/radiation, ortho- | ||||
pedic injuries and | ||||
other connective | ||||
tissue disorders | ||||
Pacific | Pennsylvania State | License | O6 benzyl guanine, | Pacific Pharmaceuticals gets |
Pharmaceuticals | University | series of compounds | exclusive worldwide license in | |
Inc. | [Anthony Pegg] | that enhance anti- | exchange for license fees, mile- | |
tumor activity of | stones (to be paid in cash or stock) | |||
chemotherapeutic | and royalties; Paramount Capital | |||
agents known as | LLC acted as financial advisor to | |||
O6 alkylators | Pacific Pharmaceuticals (3/98) | |||
(inactivates a DNA | ||||
repair enzyme) | ||||
Sarco Inc. | Duke University | Research | Small molecule | Sarco will use its combinatorial |
(wholly owned sub- | Medical Center | collaboration | compounds that | chemistry to generate and refine |
sidiary of Pharma- | [Patrick Casey] | inhibit geranyl gera- | compound libraries for further | |
ceutical Product | nyl and farnesyl | study at Duke; Sarco will spon- | ||
Development Inc.) | farnesyl transfer- | sor research and has option to | ||
ases; for treating | obtain exclusive license on any | |||
cancer | inventions (5/98) | |||
Select | Ontario Cancer | License; | Use of shiga-like | Select Therapeutics gets exclusive |
Therapeutics | Institute (Canada) | research | toxin 1 (SLT-1) as | worldwide rights to invention in |
Inc. (OTC Bulletin | [Jean Garlepy] | collaboration | agent to selectively | return for research support and |
Board: SLPU) | and University of | kill cancer cells in | royalty payments (2/98) | |
Toronto Innovation | bone marrow prior | |||
Foundation | to autologous stem | |||
cell transplants in | ||||
cancer patients | ||||
Toronto Hospital | License; | Antibiotic therapies; | Select Therapeutics will develop | |
for Sick Children | research | drugs that have been | program for synthesis and testing | |
(Canada) | collaboration | chemically modified | of new antibiotics; further details | |
to alter binding to | ND (3/98) | |||
and killing of bacterial | ||||
pathogens | ||||
StressGen | University of Miami | License | Heat shock transcrip- | StressGen licensed family of |
Biotechnologies | [Richard Voellmy] | tion factors (HSF), | international patent applications | |
Corp. (Canada) | molecules that regu- | broadly covering mutated forms of | ||
late production of | HSFs; company will develop | |||
stress proteins; to | screening assays for small mole- | |||
protect cells from | cule drugs that either up- or down- | |||
damage caused by | regulate production of stress | |||
ischemia/reperfusion | proteins (2/98) | |||
and by inflammatory | ||||
reactions | ||||
Synsorb Biotech | University of | License | High-throughput | Synsorb licensed technology and |
Inc. (Canada) | Alberta | screening technol- | has formed new subsidiary to de- | |
[Ole Hindsgaul; | ogy that determines | velop it; Synsorb will screen its | ||
David Schriemer] | if compounds have | own carbo-hybrid library but will | ||
agonist or antag- | make technology available to | |||
onist activity | other companies (5/98) | |||
T Cell Sciences | Walter Reed Army | Cooperative | Combination of | 5-year agreement; this expands on |
Inc. | Institute of Research | Research and | T Cell's comple- | earlier CRADA that tested |
(WRAIR) | Development | ment inhibition tech- | TP10's ability to inhibit comple- | |
Agreement | nology with WRAIR's | ment activation by liposome- | ||
(CRADA) | liposome drug | encapsulated hemoglobin; under | ||
delivery system to | the new CRADA, T Cell has | |||
develop hemoglobin- | exclusive rights to license all dis- | |||
containing liposomes | coveries (1/98) | |||
as emergency blood | ||||
substitute | ||||
Targeted | National Heart, | Research | Use of recombinant | Targeted Genetics will provide its |
Genetics Corp. | Lung and Blood | collaboration | adeno-associated | rAAV vector and other nonviral |
Institute (NHLBI) | viral (rAAV) vectors | vectors to NHLBI; further details | ||
of the National | as well as nonviral | ND (3/98) | ||
Institutes of Health | gene delivery vehi- | |||
cles for targeted | ||||
gene transfer to liver | ||||
tissue and other | ||||
tissues in vivo | ||||
Trega | Torrey Pines | Discontinuation | Design and syn- | Agreement dates from 1992 and |
Biosciences Inc. | Institute for | of research | thesis of small | was extended in 5/97 for 12 |
Molecular Studies | agreement | molecule combi- | months; parties agreed to terminate | |
[Richard Houghten] | natorial libraries | agreement because of divergence | ||
of respective research goals (1/98) | ||||
Tripos Inc. | The Scripps | Research | Development of | 2-year consulting and collaboration |
Research Institute | collaboration | bioinformatics soft- | agreement; Tripos gets exclusive | |
[Jeffrey Skolnick; | ware applications | distribution rights for software | ||
Adam Godzik] | for drug discovery; | (4/98) | ||
includes new Match- | ||||
Maker II software | ||||
for 3-D modeling | ||||
of protein structures | ||||
UroGenesys | University of Cali- | License | Prostate stem cell | UroGenesys gets exclusive world- |
Inc.* | fornia, Los Angeles | antigen (PSCA) gene | wide rights to gene; further details | |
[Robert Reiter] | (up-regulated only in | ND (2/98) | ||
prostate cancer) | ||||
U.S. Bioscience | National Cancer | Cooperative | Clinical develop- | U.S. Bioscience already has an |
Inc. | Institute (NCI) of | Research and | ment of lodenosine | exclusive worldwide license to |
the National Insti- | Development | (formerly FddA; | compound; NIH is conducting | |
tutes of Health (NIH) | Agreement | purine-based reverse | Phase I trials in adult and pediatric | |
[Robert Yarchoan] | (CRADA) | transcriptase inhib- | patients; U.S. Bioscience will con- | |
itor) for treating HIV | tinue clinical development and | |||
infection and AIDS | seek regulatory approval (1/98) | |||
Vaxcel Inc. | University College | License | Genetically engineered | Vaxel gets exclusive worldwide |
(OTC Bulletin | London (U.K.) | and mutated beta- | rights to technology; further | |
Board:VXCL) | human chorionic | details ND (3/98) | ||
gonadotropin pro- | ||||
teins for use as immu- | ||||
nogens in therapeutic | ||||
cancer vaccines (com- | ||||
bined with Vaxcel's | ||||
Optivax copolymer | ||||
adjuvant technology) | ||||
Vimrx | Columbia | Formation of | Drug discovery and | Parties transformed former joint |
Pharmaceuticals | University | joint venture | development com- | venture Vimrx Genomics Inc. |
Inc. | Ventiv | pany focused on re- | (gene discovery; formed 3/97) | |
Biogroup | ceptor target involved | into Ventiv Biogroup; Ventiv gets | ||
in diabetic compli- | gene discoveries already licensed | |||
cations (RAGE; | by Columbia to Vimrx Genomics, | |||
receptor for ad- | plus 3 Vimrx Pharmaceuticals | |||
vanced glycation | development programs; Ventiv is | |||
end-products) | 90% owned by Vimrx Pharma- | |||
ceuticals and 10% owned by Col- | ||||
umbia; Ventiv acquired rights to | ||||
RAGE from Columbia, in exchange | ||||
for which it will pay $2M-$3M/year | ||||
for 3 years in research support, | ||||
plus milestones and royalties; Vimrx | ||||
Genomics' gene discovery collab- | ||||
oration with Columbia (from 11/97) | ||||
will cease, along with $30M in | ||||
funding; Ventiv retains options to | ||||
certain future gene discoveries in | ||||
exchange for $5.5M in funding | ||||
over 4 years (3/98) | ||||
Vion | Yale University | Expansion of | Anticancer com- | Vion expanded collaborations |
Pharmaceuticals | [Alan Sartorelli; | two research | pounds (including | with both labs; Sartorelli gets |
Inc. | John Pawelek] | collaborations | Promycin, currently | $0.6M over 3 years to support |
in Phase III trials | research; Pawelek gets $2.56M | |||
for head and neck | over 3 years to support research | |||
cancer) that selec- | (5/98) | |||
tively target hypoxic | ||||
cancer cells (Sarto- | ||||
relli); TAPET tech- | ||||
nology (tumor ampli- | ||||
fied protein expres- | ||||
sion therapy), which | ||||
uses engineered bac- | ||||
teria to target antican- | ||||
cer therapy to solid | ||||
tumors (Pawelek) | ||||
Viragen Inc. | German Red Cross | Supply | White blood cells to | Long-term agreement; Viragen |
blood banks | agreement | be used in making | has preferential access to 100% of | |
(Germany) | Viragen's 2nd-gen- | human white blood cells collected | ||
eration multispecies | by blood banks (3/98) | |||
natural alpha inter- | ||||
feron, Omniferon | ||||
Viragen Inc. | Netherlands blood | Supply | White blood cells to | Preliminary agreement to form |
banks | agreement | be used in making | long-term exclusive supply agree- | |
(the Netherlands) | Viragen's 2nd-gen- | ment; parties also will develop a | ||
eration multispecies | natural interferon treatment pro- | |||
natural alpha inter- | gram for the Netherlands; specific | |||
feron, Omniferon | terms ND (2/98) | |||
Virus Research | Harvard University | License | Immunotherapy | Virus Research Institute gets |
Institute Inc. | delivery system | exclusive worldwide license; | ||
Therapore (consists | further details ND (1/98) | |||
of 2 bacterial pro- | ||||
teins that trans- | ||||
port polypeptides | ||||
into cells to induce | ||||
cell-mediated | ||||
immune responses) | ||||
Vysis Inc. | University Hospital | Research | Use of Vysis' DNA | Vysis gets exclusive rights to com- |
of Vrije Universiteit | collaboration | probe technology to | mercialize fetal-cell markers as | |
at Amsterdam (the | develop fetal-cell | part of its noninvasive prenatal | ||
Netherlands) | identification mark- | test; terms ND (4/98) | ||
ers (to detect genetic | ||||
abnormalities in | ||||
fetal cells present in | ||||
maternal circulation) | ||||
Xenova | The Institute of | Strategic | Establishment of | ND (1/98) |
Discovery Ltd. | Grassland and | alliance | phytochemistry | |
(subsidiary of | Environmental | group that will apply | ||
Xenova Group | Research (Wales) | Xenova's microbial | ||
plc; U.K.) | drug discovery tech- | |||
niques to search for | ||||
bioactive compounds | ||||
from European and | ||||
tropical plants | ||||
NOTES: | ||||
ASX: Australian Stock Exchange; ND = Not disclosed, reported and/or available; TSE = Toronto Stock Exchange | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 15-16. |